Thalidomide

Biological Activity

Technical Data

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.

Background References

1. Additive Renoprotection by Pioglitazone and Fenofibrate against Inflammatory, Oxidative and Apoptotic Manifestations of Cisplatin Nephrotoxicity: Modulation by PPARs.
   Helmy M, Helmy M, El-Mas M
   PLoS ONE, 2015;10(11):e0142303.
2. Inhibitors of ubiquitin E3 ligase as potential new antimalarial drug leads
   J Jain, SK Jain, LA Walker, BL Tekwani
   BMC Pharmacol Toxicol, 2017;18(1):40.
3. High-throughput genotoxicity assay identifies antioxidants as inducers of DNA damage response and cell death.
   Fox JT, Sakamuru S, Huang R
   Proc. Natl. Acad. Sci. U.S.A., 2012;109(14):5423-8.
4. Identification of a primary target of Thal. teratogenicity.
   Ito et al.
   Science, 2010;327:1345
5. Thal. promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray Syndrome.
   Donovan et al.
   Elife, 2018;7:e38430
6. Thal. reduces MPTP-induced decrease in striatal DA levels in mice.
   Boireau et al.
   Neurosci.Lett., 1997;234:123
7. Thal., a hypnotic with immune modulating properties, increases cataplexy in canine narcolepsy.
   Kanbayashi et al.
   Neuroreport, 1996;7:1881
8. Thal. inhibits the replication of human-immunodeficiency-virus type 1.
   Makonkawkeyoon et al.
   Proc.Natl.Acad.Sci.U.S.A., 1993;90:5974
9. Thal. influences growth and vasculogenic mimicry channel formation in melanoma.
   Zhang et al.
   J.Exp.Clin.Cancer Res., 2008;27:60
10. Thal. selectively inhibits tumor necrosis factor α production by stimulated human monocytes.
    Sampaio et al.
    J.Exp.Med., 1991;173:699

Product Datasheets